In a recent article published in CGTLive, Cartherics’ Prof. Alan Trounson, Karl Trounson, Dr Walid Azar and Prof. Richard Boyd, together with Dr. Alice Pebay, Principal Research Fellow, The University of Melbourne and Royal Melbourne Hospital – discuss exciting developments in immunotherapy with natural killer (NK) cells.
As the cell therapy landscape continues to evolve, NK […]
Melbourne, Australia, 18 December 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), […]
As we reflect on 2024, it’s clear that this year has been a defining chapter in Cartherics’ 10-year history. We’ve experienced significant milestones, overcome challenges, and made bold strides toward advancing our mission. The work on ovarian cancer has progressed with the autologous CAR-T product under preclinical evaluation by the Peter MacCallum Cancer Centre, […]
Cartherics’ CEO, Prof. Alan Trounson was recently interviewed by BioSpectrum Asia discussing the development of the company’s cell-based immunotherapies for cancer treatment. The article discusses:
Cartherics is frocking up this October to raise funds and awareness for crucial ovarian cancer research. The current five-year survival rate for ovarian cancer patients is just 49%. There is no early detection test and treatment options haven’t improved significantly in decades.
Cartherics’ Board Advisor and ovarian cancer survivor Heather Hawkins said, “As a survivor, I hope to […]
Melbourne, Australia, 1 October 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a […]
We are pleased to announce that Cartherics’ CEO, Prof. Alan Trounson has been recognised as a ScholarGPS Highly Ranked Scholar in recognition of his exceptional scholarly performance. His impactful work and high-quality contributions have earned him a spot in the top 0.05% of 30 million scholars globally, ranking highly across seven fields. Notably, Alan is […]
Exciting advancements are on the horizon for cancer treatment. Earlier this year, the FDA approved Lifileucel, an autologous tumor infiltrating lymphocyte (TIL) product for the treatment of melanoma. A recent article published in Drug Discovery and Development by Cartherics’ Prof. Alan Trounson and Dr. Ian Nisbet discusses how this approval marks a significant milestone in […]
Melbourne, Australia, 25 July 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), […]
In a recent interview with Wholesale Investor, Cartherics’ COO, Dr Ian Nisbet shares deep insights into the company’s groundbreaking work in developing cell therapy treatments for cancer. He discusses Cartherics’ expanding intellectual property portfolio, the impact of targeting TAG-72 on treating ovarian and gastric cancers as well as recent collaborations and the growing market for […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
